Skip to content
zameds

Cetirizine (Sinutab Sinus Allergy, Reactyne)

Cetirizine

Johnson & Johnson (Pty) Ltd û East London

Registration

Applicant
Johnson & Johnson (Pty) Ltd û East London
Registrations
4

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Sinutab sinus allergy

EACH TABLET CONTAINS CETIRIZINE DIHYDROCHLORIDE 10,0 mg

Not listed35029635/5.7.1/0296RegisteredNot determinedNone
Sinutab sinus allergy solution

EACH 1,0 ml SOLUTION CONTAINS CETIRIZINE DIHYDROCHLORIDE 1,0 mg

Solution35029835/5.7.1/0298RegisteredNot determinedNone
Sinutab sinus allergy effervescent

EACH EFFERVESCENT TABLET CONTAINS CETIRIZINE DIHYDROCHLORIDE 10,0 mg

Effervescent41042041/5.7.1/0420RegisteredNot determinedNone
Reactyne effervescent

EACH EFFERVESCENT TABLET CONTAINS CETIRIZINE DIHYDROCHLORIDE 10,0 mg

Effervescent41042641/5.7.1/0426CancelledNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S1: Cetirizine

    Consolidated Schedules 06 July 2026, line 318

5 of 11 approved products with this ingredient carry S2 on their leaflet.

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C21H25ClN2O3388.90 g/mol

2-[2-[4-[(4-Chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid

Drag to rotate. Structure from PubChem CID 2678.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles